Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.37 |
| ▸ | ACACB | O00763 | 4/20 | 0.33 |
| ▸ | ACACA | Q13085 | 2/20 | 0.33 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.33 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20038252 | 1.00 | CYP4F2 (0.43) | CYP4F2CYP4A11IRAK4ACACBACACA | |
| SCHEMBL20037527 | 1.00 | CYP4F2 (0.43) | CYP4F2CYP4A11IRAK4ACACBACACA | |
| SCHEMBL19837299 | 0.87 | CYP4F2 (0.36) | CYP4F2CYP4A11ACACBACACAMBOAT4 | |
| SCHEMBL18291367 | 0.82 | CYP4F2 (0.43) | CYP4F2CYP4A11IRAK4ACACBACACA | |
| SCHEMBL18291349 | 0.82 | CYP4F2 (0.43) | CYP4F2CYP4A11IRAK4ACACBACACA | |
| SCHEMBL20038376 | 0.79 | CHRM4 (0.43) | CYP4F2CYP4A11CHRM4 | |
| SCHEMBL20249451 | 0.79 | CYP4F2 (0.41) | CYP4F2CYP4A11IRAK4ACACBACACA | |
| SCHEMBL20249477 | 0.79 | CYP4F2 (0.41) | CYP4F2CYP4A11IRAK4ACACBACACA | |
| SCHEMBL20037515 | 0.79 | CYP4F2 (0.41) | CYP4F2CYP4A11ACACBACACAMBOAT4 | |
| SCHEMBL20038324 | 0.79 | CYP4F2 (0.41) | CYP4F2CYP4A11ACACBACACAMBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | CYP4F2 805/4885CYP4A11 371/4885IRAK4 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.